
Acute MI Prevalence: 2023 female 0.0014 Baseline Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 -65_to_69 -55_to_59 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 50_to_54 70_to_74 75_to_79 80_to_84 85_to_89 95_plus 25_to_29

Acute MI Prevalence: 2024 female Baseline Lifestyle 0.0012 Outreach Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 55_to_59 60_to_64 30_to_34 35_to_39 40_to_44 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 80_to_84 85_to_89 95_plus 25_to_29




Acute MI Prevalence: 2026 female Baseline 0.0014 Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 40_to_44 -60_to_64 · 55_to_59 _to_89 35_to_39 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 95_plus 25_to_29 82

Acute MI Prevalence: 2027 female 0.0016 Baseline Lifestyle 0.0014 Outreach Polypill 0.0012 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 60_to_64 · _to_89. 25_to_29 35_to_39 40_to_44 45_to_49 50_to_54 55_to_59 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 82

Acute MI Prevalence: 2028 female Baseline 0.0014 Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 -40_to_44 -75_to_79 -55_to_59 60_to_64 30_to_34 35_to_39 45_to_49 50_to_54 65_to_69 70_to_74 80_to_84 85_to_89 95_plus 25_to_29


Acute MI Prevalence: 2029 female 0.0014 Baseline Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 40_to_44 -60_to_64 · 55_to_59 _to_89 35_to_39 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 25_to_29 82




Acute MI Prevalence: 2031 female 0.0014 Baseline Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 40_to_44 -55_to_59 60_to_64 _to_89 25_to_29 30_to_34 35_to_39 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 82

Acute MI Prevalence: 2032 female Baseline 0.0014 Lifestyle Outreach Polypill 0.0012 0.0010 8000.0 0.0006 0.0004 0.0002 0.0000 55_to_59 _to_89 40_to_44 45_to_49 50_to_54 60_to_64 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 25_to_29 82

Acute MI Prevalence: 2033 female 0.0014 Baseline Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 -55_to_59 60_to_64 _to_89 35_to_39 40_to_44 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 25_to_29 82




Acute MI Prevalence: 2035 female Baseline 0.0014 Lifestyle Outreach 0.0012 Polypill 0.0010 8000.0 0.0006 0.0004 0.0002 0.0000 -60_to_64 · 75_to_79 -80_to_84 · 55_to_59 _to_89 35_to_39 40_to_44 45_to_49 50_to_54 65_to_69 70_to_74 95_plus 25_to_29 82





Acute MI Prevalence: 2037 female Baseline 0.0014 Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 -60_to_64 · 80_to_84 · _to_89 . 55_to_59 30_to_34 35_to_39 40_to_44 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 95_plus 25_to_29 82


Acute MI Prevalence: 2038 female Baseline 0.0014 Lifestyle Outreach 0.0012 Polypill 0.0010 0.0008 0.0006 0.0004 0.0002 0.0000 40_to_44 -_to_89 . 55_to_59 60_to_64 25_to_29 35_to_39 45_to_49 50_to_54 65_to_69 70_to_74 75_to_79 80_to_84 95_plus 82


Acute MI Prevalence: 2039 female 0.0012 Baseline Lifestyle Outreach 0.0010 Polypill 0.0008 0.0006 0.0004 0.0002 0.0000 65_to_69 -55_to_59 60_to_64 _to_89 30_to_34 35_to_39 40_to_44 45_to_49 50_to_54 70_to_74 75_to_79 80_to_84 95_plus 25_to_29 82















































Acute MI Prevalence: 2039 male Baseline 0.00200 Lifestyle Outreach 0.00175 Polypill 0.00150 0.00125 0.00100 0.00075 0.00050 0.00025 0.00000 40_to_44 -65_to_69 -70_to_74 · 75_to_79 · 45_to_49 35_to_39 50_to_54 55_to_59 60_to_64 80_to_84 85_to_89 95_plus 25_to_29

